ECE2020 Audio ePoster Presentations Pituitary and Neuroendocrinology (217 abstracts)
SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors
Solene Castellnou 1,2 , Alexandre Vasiljevic 2,3,4 , Veronique Lapras 5 , Véronique Raverot 6 , Eudeline Alix 7 , Francoise Borson-Chazot 1,2 , Emmanuel Jouanneau 2,4,8 , Gerald Raverot 1,2,4 & Lasolle Hélène 1,2,4
1Groupement Hospitalier Est, Hospices Civils de Lyon, Service d’Endocrinologie, Bron, France; 2Université Claude Bernard Lyon 1, Villeurbanne, France; 3Groupement Hospitalier Est, Hospices Civils de Lyon, Centre de Pathologie Est, Bron, France; 4Cancer Research Center of Lyon, INSERM U1052, CNRS, UMR5286, Lyon, France; 5Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Service de Radiologie, Pierre-Bénite, France; 6Groupement Hospitalier Est, Hospices Civils de Lyon, Centre de Biologie Est, Bron, France; 7Groupement Hospitalier Est, Hospices Civils de Lyon, Département de cytogénétique, Bron, France; 8Groupement Hospitalier Est, Hospices Civils de Lyon, Service de Neurochirurgie, Bron, France
Context: Somatostatin receptor type 5 (SST5) is inconsistently expressed by corticotroph tumors, with higher expression found in corticotropinomas having ubiquitin-specific protease 8 (USP8) mutations.
Aims: To study the correlation between characteristics of corticotropinomasand SST5 expression/USP8 mutation status; to describe the response to pasireotide in 5 patients.
Design: Retrospective cohort study.
Methods: Clinico-biochemical, radiological and pathological data of 62 patients, operated for a functioning orsilent corticotropinoma between 2013 and 2017, were collected. SST5 expression was measured by immunohistochemistry (clone UMB-4, Abcam, IRS > 1 being considered positive) and Sanger sequencing was performed on 50 tumors to screen for USP8 mutations.
Results: SST5 expression was positive in 26 (41.9%) pituitary tumors. A moderate or strong IRS was found in 25.9% of the cohort and in 37.1% of the functioning corticotropinomas. Among functioning tumors, those expressing SST5 were more frequent in women (91.7% vs 60%; P = 0.004) and had a lower grade (P = 0.04) compared to others. USP8 mutations were identified in 26% of the cohort and were more frequent in functioning (n = 11/30, 36.7%) compared to silent tumors (n = 2/20, 10%; P = 0.05). SST5 expression was more frequent in USP8 mut vs USP8wt tumors (90.9% vs 36.8%; P = 0.007). Among treated patients, normal urinary free cortisol levels were obtained in 3 patients (IRS 0, 2, 6) while a 4.5-fold decrease was observed in one patient (IRS 4).
Conclusion: SST5 expression appears to be associated with functioning, USP8 mutand lower grade corticotropinomas. A correlation between SST5 expression or USP8 mut and response to pasireotide remains to be confirmed.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more